d-0120
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 13, 2017 (NCT03291782)
Timeline
Indications
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
SLC22A12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05665699 | Phase 2 | Feb 27, 2023 | InventisBio Inc. |
| NCT05504083 | Phase 2 | Aug 25, 2022 | Chinese Academy of Medical Sciences, InventisBio Inc. |
| NCT05360628 | Early Phase 1 (Phase 1) | Nov 1, 2021 | InventisBio Inc. |
| NCT04097405 | Phase 1 | Sep 18, 2019 | InventisBio Inc. |
| NCT03923868 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2019 | InventisBio Inc. |
| NCT03291782 | Phase 1 | Sep 13, 2017 | Covance, InventisBio Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InventisBio Inc. | For profit | 6 | 6 | 2 | 2017 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Covance | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1